Scholarlink

<p>Data describing outcomes of teclistamab in multiple myeloma patients with prior exposure to BCMA-directed therapy (BCMA-DT) are limited. The goal of this multicenter retrospective analysis was to report the efficacy and safety of standard-of-care teclistamab in patients with prior BCMA-DT. A total of 385 patients were included, of whom 193 (50%) had received prior BCMA-DT, including 47 (24%) patients with prior antibody-drug conjugate (ADC)-only, 99 (51%) with chimeric antigen receptor T-cell therapy (CAR T)-only, 36 (19%) with both ADC and CAR T, 6 (3%) with bispecific antibody-only, and 5 (3%) with other combinations. Most safety parameters between cohorts were comparable. The prior BCMA-DT cohort had a lower overall response rate (ORR: 48.7% versus 61.5%; <i>p</i> = 0.012), and median progression-free survival (PFS: 4.6 versus 8.2 months; <i>p</i> = 0.017) compared to the cohort without prior BCMA-DT. However, in multivariable analysis, despite a clear trend, ultimately receipt of a prior BCMA-DT was not independently associated with ORR or PFS (<i>p</i> = 0.057 and <i>p</i> = 0.1, respectively). No significant differences in PFS were noted when stratifying patients by number of prior BCMA-DTs, types of all prior BCMA-DTs received, type of most recent prior BCMA-DT, or depth of response to most recent BCMA-DT. Using the maximally selected rank statistics method, the optimal cut-off for time from the last BCMA-DT exposure to teclistamab initiation was identified as 8.7 months. Patients with &gt;8.7 months between their last exposure to prior BCMA-DT and teclistamab initiation had a significantly improved median PFS with teclistamab (8.1 months, 95% CI: 4.6–11.7) compared to patients with &lt;8.7 months (2.5 months, 95% CI: 1.1–5.7), <i>p</i> = 0.001. Altogether, our findings support the use of teclistamab as a viable treatment option in patients previously exposed to BCMA-DT.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月25日

查看全文
  • Danai Dima,
  • Mariola A. Vazquez-Martinez,
  • James A. Davis,
  • Utkarsh Goel,
  • Aimaz Afrough,
  • Aishwarya Sannareddy,
  • Oren Pasvolsky,
  • Beatrice Razzo,
  • Rahul Banerjee,
  • Jack Khouri,
  • Ariel Grajales-Cruz,
  • Alex Lieberman-Cribbin,
  • Masooma Shifa Rana,
  • Kelley Julian,
  • Shaun DeJarnette,
  • Andrew J. Portuguese,
  • Mahmoud R. Gaballa,
  • Gabriel De Avila,
  • Sandra Susaniba Adaniya,
  • Shahzad Raza,
  • Megan M. Herr,
  • Evguenia Ouchveridze,
  • Tiffany Richards,
  • Hitomi Hosoya,
  • Lekha Mikkilineni,
  • Gurbakhash Kaur,
  • Omar Castaneda Puglianini,
  • Adriana Rossi,
  • Yi Lin,
  • Shebli Atrash,
  • Douglas Sborov,
  • Kenneth H. Shain,
  • Peter M. Voorhees,
  • Shambavi Richard,
  • Alfred L. Garfall,
  • Doris K. Hansen,
  • Surbhi Sidana,
  • Krina K. Patel,
  • Andrew J. Cowan,
  • Larry D. Anderson Jr,
  • Hans C. Lee,
  • Faiz Anwer,
  • Christopher J. Ferreri,
  • Leyla Shune

摘要

Data describing outcomes of teclistamab in multiple myeloma patients with prior exposure to BCMA-directed therapy (BCMA-DT) are limited. The goal of this multicenter retrospective analysis was to report the efficacy and safety of standard-of-care teclistamab in patients with prior BCMA-DT. A total of 385 patients were included, of whom 193 (50%) had received prior BCMA-DT, including 47 (24%) patients with prior antibody-drug conjugate (ADC)-only, 99 (51%) with chimeric antigen receptor T-cell therapy (CAR T)-only, 36 (19%) with both ADC and CAR T, 6 (3%) with bispecific antibody-only, and 5 (3%) with other combinations. Most safety parameters between cohorts were comparable. The prior BCMA-DT cohort had a lower overall response rate (ORR: 48.7% versus 61.5%; p = 0.012), and median progression-free survival (PFS: 4.6 versus 8.2 months; p = 0.017) compared to the cohort without prior BCMA-DT. However, in multivariable analysis, despite a clear trend, ultimately receipt of a prior BCMA-DT was not independently associated with ORR or PFS (p = 0.057 and p = 0.1, respectively). No significant differences in PFS were noted when stratifying patients by number of prior BCMA-DTs, types of all prior BCMA-DTs received, type of most recent prior BCMA-DT, or depth of response to most recent BCMA-DT. Using the maximally selected rank statistics method, the optimal cut-off for time from the last BCMA-DT exposure to teclistamab initiation was identified as 8.7 months. Patients with >8.7 months between their last exposure to prior BCMA-DT and teclistamab initiation had a significantly improved median PFS with teclistamab (8.1 months, 95% CI: 4.6–11.7) compared to patients with <8.7 months (2.5 months, 95% CI: 1.1–5.7), p = 0.001. Altogether, our findings support the use of teclistamab as a viable treatment option in patients previously exposed to BCMA-DT.